

Supplemental Table 1 Patient and tumor characteristics for non-cirrhotic HCC by body mass index class

Variable	BMI < 25 (kg/m ²)	BMI 25.0-29.9 (kg/m ²)	BMI ≥ 30 (kg/m ²)	P-value
	(N=100)	(N=94)	(N=92)	
Age (Years)	66.3 ± 14.1	69.2 ± 12.7	66.8 ± 9.3	0.22
Sex of the patient				
- Male	65 (65.0%)	73 (77.7%)	62 (67.4%)	0.13
- Female	35 (35%)	21 (22.3%)	30 (32.6%)	
Race				
- White	72 (72%)	73 (79.3%)	81 (88.0%)	0.015
- Black	21 (21.0%)	9 (9.8%)	8 (8.7%)	
- Hispanic	1 (1.0%)	6 (6.5%)	1 (1.1%)	
- Asian	6 (6.0%)	4 (4.3%)	2 (2.2%)	
MELD-Na Score	8.7 ± 3.8	9.7 ± 3.9	9.4 ± 3.8	0.22
Tumor size (cm)	9.2 ± 5.5	7.6 ± 4.6	7.7 ± 4.6	0.058
Etiology of Chronic Liver Disease				
- HCV	20 (20.0%)	18 (19.2%)	11(11.9%)	0.42
- Alcohol alone	2 (2.0%)	6 (6.4%)	5 (5.4%)	
- NAFLD	15 (15.0%)	20 (21.3%)	31 (33.7%)	
- AIH/PBC/PSC	0 (0.0%)	0 (0.0%)	1 (1.1%)	
- HBV	7 (7.0%)	5 (5.3%)	2 (2.2%)	
- HC/A1AT	2 (2.0%)	1 (1.1%)	0 (0.0%)	
- Unknown	54 (54.0%)	42 (44.7%)	41 (45.6%)	
AFP (ng/mL) category				
- < 20	43 (50.6%)	52 (62.7%)	45 (57.7%)	0.42
- 20-200	12 (14.1%)	13 (15.7%)	11 (14.1%)	
- > 200	30 (35.3%)	18 (21.7%)	22 (28.2%)	
APRI Index Categorized				

Variable	BMI			P-value
	BMI < 25 (kg/m ²) (N=100)	25.0-29.9 BMI (kg/m ²) (N=94)	BMI ≥ 30 (kg/m ²) (N=92)	
- < 1.0	77 (79.4%)	68 (73.1%)	78 (84.8%)	0.26
- 1.0-2.0	12 (12.4%)	11 (11.8%)	8 (8.7%)	
- > 2.0	8 (8.2%)	14 (15.1%)	6 (6.5%)	
Tumor Stage				
- Single	51 (51.5%)	46 (48.9%)	49 (53.3%)	0.83
- 3 tumors < 3 cm	1 (1.0%)	0 (0.0%)	1 (1.1%)	
- Large multinodular	21 (21.2%)	27 (28.7%)	23 (25.0%)	
- Vascular invasion or extrahepatic spread	26 (26.3%)	21 (22.3%)	19 (20.7%)	
Evidence of screening within 2 years				
- Yes	12 (14.1%)	9 (10.7%)	10 (13.5%)	0.87
- No	64 (75.3%)	67 (79.8%)	54 (73.0%)	
- Unknown	9 (10.6%)	8 (9.5%)	10 (13.5%)	

BMI: Body mass index; MELD: Model for end-stage liver disease; HCV: Hepatitis C virus; NAFLD: Non-alcoholic fatty liver disease; AIH: Autoimmune hepatitis; PBC: Primary biliary cholangitis; PSC: Primary sclerosing cholangitis; HBV: Hepatitis B virus; HC: Hemochromatosis; A1AT: Alpha 1 antitrypsin deficiency; AFP: Alpha fetoprotein; APRI: AST to platelet ratio